These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31025878)

  • 1. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen.
    Bergenstal RM; Peyrot M; Dreon DM; Aroda VR; Bailey TS; Brazg RL; Frias JP; Johnson ML; Klonoff DC; Kruger DF; Ramtoola S; Rosenstock J; Serusclat P; Weinstock RS; Naik RG; Shearer DM; Zraick V; Levy BL;
    Diabetes Technol Ther; 2019 May; 21(5):273-285. PubMed ID: 31025878
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study.
    Bohannon N; Bergenstal R; Cuddihy R; Kruger D; List S; Massaro E; Molitch M; Raskin P; Remtema H; Strowig S; Whitehouse F; Brunelle RL; Dreon D; Tan M
    Diabetes Technol Ther; 2011 Oct; 13(10):1031-7. PubMed ID: 21732797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles.
    Bergenstal RM; Johnson ML; Aroda VR; Brazg RL; Dreon DM; Frias JP; Kruger DF; Molitch ME; Mullen DM; Peyrot M; Richter S; Rosenstock J; Serusclat P; Vance C; Weinstock RS; Levy BL
    J Diabetes Sci Technol; 2022 Sep; 16(5):1167-1173. PubMed ID: 34008442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes.
    Ahmann A; Szeinbach SL; Gill J; Traylor L; Garg SK
    Diabetes Technol Ther; 2014 Feb; 16(2):76-83. PubMed ID: 24266497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Wang C; Mamza J; Idris I
    Diabet Med; 2015 May; 32(5):585-94. PubMed ID: 25594251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
    Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
    Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study Protocol for a Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of a Needle-Free Insulin Injector and a Conventional Insulin Pen in Controlling Blood Glucose Concentrations in Chinese Patients with Type 2 Diabetes Mellitus (The FREE Study).
    Ji L; Chen L; Wang Y; Ma Z; Ran X; Sun Z; Xu X; Wang G; Guo L; Shan Z
    Adv Ther; 2019 Jun; 36(6):1485-1496. PubMed ID: 31004325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data.
    Anyanwagu U; Mamza J; Gordon J; Donnelly R; Idris I
    Diabet Med; 2017 Dec; 34(12):1728-1736. PubMed ID: 28945928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch.
    Peyrot M; Dreon D; Zraick V; Cross B; Tan MH
    Diabetes Ther; 2018 Feb; 9(1):297-307. PubMed ID: 29327220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study.
    Raskin P; Bode BW; Marks JB; Hirsch IB; Weinstein RL; McGill JB; Peterson GE; Mudaliar SR; Reinhardt RR
    Diabetes Care; 2003 Sep; 26(9):2598-603. PubMed ID: 12941725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W; Ji Q; Zhu D; Yang J; Chen L; Liu Z; Yu D; Yan L
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Effectiveness of an Investigational Insulin Delivery Device Providing Basal/Bolus Therapy with Rapid-Acting or Regular Human Insulin in Adults with Type 2 Diabetes.
    Aronson R; Mahoney E; Saliu D; Sze D; Morel D; Bergquist L; Hirsch L
    Diabetes Technol Ther; 2020 May; 22(5):352-359. PubMed ID: 31692373
    [No Abstract]   [Full Text] [Related]  

  • 14. Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin.
    Wang T; Conrad KA; van Brunt K; Rees TM
    J Diabetes Sci Technol; 2016 Jul; 10(4):923-31. PubMed ID: 26920640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes.
    Pohlmeier H; Berard L; Brulle-Wohlhueter C; Wu J; Dahmen R; Nowotny I; Klonoff D
    J Diabetes Sci Technol; 2017 Mar; 11(2):263-269. PubMed ID: 27664062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preference for a new prefilled insulin pen compared with the original pen.
    Garg S; Bailey T; DeLuzio T; Pollom D
    Curr Med Res Opin; 2011 Dec; 27(12):2323-33. PubMed ID: 21988614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized intensification of insulin therapy in type 2 diabetes - does a basal-bolus regimen suit all patients?
    Giugliano D; Sieradzki J; Stefanski A; Gentilella R
    Curr Med Res Opin; 2016 Aug; 32(8):1425-34. PubMed ID: 27126277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label study.
    Danne T; Forst T; Deinhard J; Rose L; Moennig E; Haupt A
    J Diabetes Sci Technol; 2012 Nov; 6(6):1392-7. PubMed ID: 23294785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expectations about insulin therapy, perceived insulin-delivery system social acceptability, and insulin treatment satisfaction contribute to decreases in insulin therapy self-efficacy in patients with type 2 diabetes after 36 weeks insulin therapy.
    Hayes RP; Curtis B; Ilag L; Nelson DR; Wong M; Funnell M
    J Diabetes; 2013 Sep; 5(3):358-67. PubMed ID: 23489710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.